Results 11 to 20 of about 9,316,170 (262)

Setting a research agenda for progressive multiple sclerosis: The International Collaborative on Progressive MS [PDF]

, 2012
Despite significant progress in the development of therapies for relapsing MS, progressive MS remains comparatively disappointing. Our objective, in this paper, is to review the current challenges in developing therapies for progressive MS and identify ...
Salvetti, M, D. Brown, T. Coetzee, K. Sharrock, Lee, K, Brown, D, Feinstein, A, Thompson, A, K. Zuidwijk, D. Chandraratna, Kapoor, R, Fox, RJ, Zuidwijk, K, K. Lee, A. Thompson, G. Comi, Toosy, A, Baneke, P, Browne, P, Sharrock, K, O. Ciccarelli, P. Browne, A. Feinstein, Comi, G, R. J. Fox, Chandraratna, D, P. Zaratin, Baker, D, R. Kapoor, Ciccarelli, O, Zaratin, P, P. Baneke, Coetzee, T, D. Baker, SALVETTI, Marco, A. Toosy   +35 more
core   +1 more source

External validation of a clinical prediction model in multiple sclerosis [PDF]

, 2023
Background: Timely initiation of disease modifying therapy is crucial for managing multiple sclerosis (MS). Objective: We aimed to validate a previously published predictive model of individual treatment response using a non-overlapping cohort from the ...
Inshasi, Jihad, Malpas, Charles B, Yamout, Bassem I., Altıntaş, Ayşe, Yamout, Bassem, Türkoǧlu, Recai, Sharmin, Sifat, Shalaby, Nevin Mohieldin, Karabudak, Rana, Al-Harbi, Talal, Shalaby, Nevin, Shaygannejad, Vahid, Khoury, Samia J., Khoury, Samia J, Boz, Cavit, Soysal, Aysun, Alroughani, Raed, Inshasi, Jihad Said, Terzi, Murat, Moradi, Nahid, Malpas, Charles B., Alroughani, Raed A., Al-Harbi, Talal M., Kalincik, Tomas, Altintaş, Ayşe   +24 more
core   +1 more source

Serum S100B in primary progressive multiple sclerosis patients treated with interferon-beta-1a. [PDF]

, 2004
S100B belongs to a family of calcium-binding proteins implicated in intracellular and extracellular regulatory activities. This study of serum S100B in primary progressive multiple sclerosis (PPMS) is based on data obtained from a randomized, controlled ...
Lim, Ee Tuan, Leary, Siobhan M, Geoff Keir, Petzold, Axel, Thompson, Alan J, Gavin Giovannoni, Siobhan M Leary, Altmann, Daniel R, Keir, Geoff, Ee Tuan Lim, David H Miller, Ed J Thompson, Giovannoni, Gavin, Miller, David H, Alan J Thompson, Daniel R Altmann, Thompson, Ed J, Axel Petzold   +17 more
core   +2 more sources

OCRELIZUMAB IN THE TREATMENT OF PRIMARY-PROGRESSIVE MULTIPLE SCLEROSIS

Медицинский совет, 2018
This article presents the review of results of clinical trials of drugs for pathogenetic therapy of primary progressive multiple sclerosis, including ocrelizumab.
E. V. Popova
doaj   +1 more source

T2 lesion location really matters: a 10 year follow-up study in primary progressive multiple sclerosis [PDF]

, 2010
Objectives: Prediction of long term clinical outcome in patients with primary progressive multiple sclerosis (PPMS) using imaging has important clinical implications, but remains challenging.
Polman, C., Barkhof, F., Montalban, X, CHARD D, Thompson, A, Polman, C, F. Barkhof, Chard, D, Samson, R., D. Miller, Bodini, B., A. Thompson, Samson, R, MONTALBAN X, R. Samson, Rovira, A, POLMAN C, KHALEELI Z, O. Ciccarelli, Filippi, M., N. De Stefano, Barkhof, F, BATTAGLINI, MARCO, B. Bodini, A. Rovira, Battaglini, M, Polman, C.H., Chard, D., CICCARELLI O., Miller, D., Rovaris, M, Battaglini, M., Thompson, A., De Stefano, N., X. Montalban, MILLER D, ROVARIS M, FILIPPI M, D. Chard, Khaleeli, Z, SAMSON R, ROVIRA A, THOMPSON A, Rovaris, M., De Stefano, N, Rovira, A., Z. Khaleeli, Bodini, B, BODINI B, M. Filippi, Miller, D, BARKHOF F, DE STEFANO, NICOLA, M. Rovaris, Montalban, X., Ciccarelli, O., Ciccarelli, O, Khaleeli, Z., M. Battaglini, C. Polman, Filippi, M, Rovira, Alex, Stefano, N. De, Rovaris, Marco, Thompson, Alan, De Stefano N, Battaglini M, FILIPPI , MASSIMO, Barkhof, Frederik, Polman, Chris, Montalban, Xavier, Ciccarelli, Olga, Miller, David, Filippi, Massimo, Khaleeli, Zhaleh, Chard, Declan, Filippi, M., Bodini, Benedetta, Samson, Rebecca   +78 more
core   +1 more source

Cerebrospinal fluid ATP metabolites in multiple sclerosis [PDF]

, 2010
Increased axonal energy demand and mitochondrial failure have been suggested as possible causes for axonal degeneration and disability in multiple sclerosis.Our objective was to test whether ATP depletion precedes clinical, imaging and biomarker evidence
Uitdehaag, BMJ, Di Pietro, V., Barkhof, F., Killestein, J, Belli, A.; id_orcid, Killestein, J., Uitdehaag, B.M.J., Eikelenboom, M.J., University of Catania, Tavazzi, B, Petzold, A.F.S., Petzold, A., Petzold, A, Belli, A., Eikelenboom, MJ, Lazzarino, G., Lazzarino, G, Di Pietro, V, Polman, CH, Amorini, A.M., Barkhof, F, Tavazzi, B., Polman, C.H., Belli, A, Di Pietro, V.; id_orcid, Amorini, AM, Pietro, V. Di   +26 more
core   +1 more source

The Role of B Cells in Primary Progressive Multiple Sclerosis

Frontiers in Neurology, 2021
The success of ocrelizumab in reducing confirmed disability accumulation in primary progressive multiple sclerosis (PPMS) via CD20-targeted depletion implicates B cells as causal agents in the pathogenesis of PPMS.
Jameson P. Holloman, Robert C. Axtell, Robert C. Axtell, Nancy L. Monson, Nancy L. Monson, Gregory F. Wu, Gregory F. Wu   +6 more
doaj   +1 more source

Possible effects of electroconvulsive therapy on refractory psychosis in primary progressive multiple sclerosis: A case report

Neuropsychopharmacology Reports, 2018
Introduction Patients with multiple sclerosis commonly show some degree of psychiatric symptoms. Primary progressive multiple sclerosis is a part of the spectrum of multiple sclerosis phenotypes with progressive accumulation of disability from disease ...
Zui Narita, Naoko Satake, Wakiro Sato, Harumasa Takano   +3 more
doaj   +1 more source

Comparison of recent updates in genetics, immunology, biomarkers, and neuroimaging of primary‐progressive and relapsing‐remitting multiple sclerosis and the role of ocrelizumab in the management of their refractory cases

Health Science Reports, 2023
Background Primary‐progressive multiple sclerosis (PPMS) and relapsing‐remitting multiple sclerosis (RRMS) are two frequent multiple sclerosis (MS) subtypes that involve 10%–15% of patients. PPMS progresses slowly and is diagnosed later in life.
Priyadarshi Prajjwal, Mohammed Dheyaa Marsool Marsool, Shahnaz Asharaf, Pugazhendi Inban, Srikanth Gadam, Rukesh Yadav, Neel Vora, Varsha Nandwana, Ali Dheyaa Marsool Marsool, Omniat Amir   +9 more
doaj   +1 more source

Progressive dopaminergic defect in a patient with primary progressive multiple sclerosis [PDF]

, 2022
Dopamine has a modulatory role in a number of autoimmune diseases, but there are no published cases of longitudinal dopaminergic imaging in multiple sclerosis (MS).
Soilu-Hänninen Merja, Noponen Tommi, Kaasinen Valtteri, Joutsa Juho, Airas Laura, Rissanen Eero   +5 more
core   +1 more source